What is Inhibrx Biosciences, Inc.'s G&A?

Inhibrx Biosciences, Inc. (INBX) reported G&A of $5.71M in Q1 2026.

How has Inhibrx Biosciences, Inc.'s G&A changed year-over-year?

Inhibrx Biosciences, Inc.'s G&A decreased by 5.2% year-over-year, from $6.02M to $5.71M.

What is the long-term trend for Inhibrx Biosciences, Inc.'s G&A?

Over 2 years (2023 to 2025), Inhibrx Biosciences, Inc.'s G&A has grown at a -11.0% compound annual growth rate (CAGR), from $29.38M to $23.3M.

Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.

Inhibrx Biosciences, Inc. INBX G&A

G&A at other companies

ArriVent BioPharma, Inc.AVBP

$8.49M+54.9%

ImmunomeIMNM

$12.95M+21.1%

Replimune GroupREPL

$18.73M+4.0%

Arcus BiosciencesRCUS

$29M+3.6%

IDEAYA Biosciences, Inc.IDYA

$19.38M+43.5%

Erasca, Inc.ERAS

$10.65M+10.2%

Segments

By segment

See full

Reportable Segment$5.71M-5.2%

Other financials

Income statement

See full

Revenue--100%

Operating income-$30.9M+27.9%

Net income-$33.4M+22.8%

EPS (diluted)-$2.15+23.2%

Balance sheet

See full

Cash & equivalents$161.7M-25.3%

Total debt$180.9M+69.8%

Total equity-$21.0M-122%

Total assets$184.0M-24.2%

Cash flow

See full

Operating cash flow-$38.0M-5.9%

CapEx--100%

Free cash flow-$38.0M-5.9%

Valuation

See full

Market cap$1.4B+546%

Enterprise value$1.42B+1,233%

P/S1,073.7×-280×

Profitability

See full

Operating margin-10,386.5%-5,025pp

Net margin-10,773.5%-878,492pp

FCF margin-9,986.5%-4,727pp

Returns & leverage

See full

Return on equity-197.8%-2,158pp

Debt / equity13.4×+13.3×

Current ratio6.5×+1.3×

Where this comes from

Reported directly by Inhibrx Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: Inhibrx Biosciences, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Inhibrx Biosciences, Inc.'s g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Inhibrx Biosciences, Inc.'s G&A?: Inhibrx Biosciences, Inc. (INBX) reported G&A of $5.71M in Q1 2026.
How has Inhibrx Biosciences, Inc.'s G&A changed year-over-year?: Inhibrx Biosciences, Inc.'s G&A decreased by 5.2% year-over-year, from $6.02M to $5.71M.
What is the long-term trend for Inhibrx Biosciences, Inc.'s G&A?: Over 2 years (2023 to 2025), Inhibrx Biosciences, Inc.'s G&A has grown at a -11.0% compound annual growth rate (CAGR), from $29.38M to $23.3M.
What does G&A mean?: Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.